A new way to prevent cancer drugs from stopping working
A novel strategy to overcome drug resistance in cancer
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA-IRVINE · NIH-11312558
This project develops a compound called SH-BC-893 that hits multiple cancer survival pathways to try to stop tumors from becoming resistant to targeted treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA-IRVINE (nih funded) |
| Locations | 1 site (IRVINE, UNITED STATES) |
| Trial ID | NIH-11312558 on ClinicalTrials.gov |
What this research studies
You should know this work is happening in the lab and in animal models, not yet as a treatment for people. Researchers are using single-cell sequencing, biochemical assays, and preclinical tests to understand how some tumor cells survive targeted drugs and to see whether SH-BC-893 can kill those escape cells by acting on several signaling pathways at once. The team aims to create a more robust therapy that keeps working even when parts of a tumor change. If results are promising, the next steps would be formal clinical trials to test safety and benefit in patients.
Who could benefit from this research
Good fit: Ideal candidates would be people with cancers that have stopped responding to targeted therapies or whose tumors show resistance-related changes.
Not a fit: Patients with cancers driven by unrelated mechanisms or who need immediate approved treatments may not benefit from this preclinical work.
Why it matters
Potential benefit: If successful, this approach could lead to therapies that keep cancers from becoming drug-resistant and extend the time patients benefit from treatment.
How similar studies have performed: Related multi-target strategies and sphingolipid-like compounds have shown promising results in laboratory and animal studies, but they are not yet proven in people.
Where this research is happening
IRVINE, UNITED STATES
- UNIVERSITY OF CALIFORNIA-IRVINE — IRVINE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: EDINGER, AIMEE L — UNIVERSITY OF CALIFORNIA-IRVINE
- Study coordinator: EDINGER, AIMEE L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents